Q-omics provides the consensus-scored RPS6P23 profile across patient tissues and cancer cell-line models. RPS6P23 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS6P23 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, RPS6P23 RNA expression shows 6,195 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, BRCA, and STAD as cancer lineages where RPS6P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6P23 survival associations across molecular data types. RPS6P23 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6P23 RNA expression–survival associations across cancer types. High RPS6P23 expression shows unfavorable associations in LIHC, KIRC, READ, BLCA and STAD, but favorable associations in HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS6P23 RNA expression.
This table summarizes RPS6P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS6P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6P23 shows lower tumor expression in BRCA and higher tumor expression in PRAD and LUAD. The BRCA box plot shows higher RPS6P23 RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .017).
This table shows molecular features associated with RPS6P23 in patient tissues and cancer cell lines. In patient samples, RPS6P23 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
